Description: Learn from panelists from different companies as they come together to discuss their experiences.

Description: Focus on the importance of achieving complete and accurate technical reviews of work products that contribute to decision making. As actuaries, we often face tight deadlines and the demand is high for our team members to provide results in a timely manner. Through investing upfront time into a quality review of our work product, with an added focus on professional excellence and ethics, overall time savings can be gained and an overall higher quality work product can be achieved, not only of the technical work being performed, but of the decision making that is influenced by the result of the work. At the conclusion of this session, you will be able to understand the value of technical reviews and the methods of preparing for and implementing technical reviews across a team.

Description: Generative artificial intelligence (AI) tools like ChatGPT will redefine the nature of work across industries in coming years, What does this mean for the actuarial profession? Delivering generative AI tools to actuaries capable of leveraging them effectively will dramatically modernize how actuaries work and contribute to organizational growth. In this educational session, explore how generative AI can accelerate actuarial model development. Gain an introduction to generative AI and its implications for actuarial modeling. Learn how it specifically helps actuaries improve accuracy, reduce errors and save time in model development. Then explore use cases, including how generative AI can improve data cleaning, model building, as well as simulate scenarios and test model robustness. Close with a discussion on how to integrate generative AI into actuarial modeling workflows effectively, including common challenges actuaries may face during implementation and tips to overcome them. You will come away with a deeper understanding of how generative AI can accelerate actuarial model development.

Description: Risk adjustment in government regulated health plans has been around for over two decades. Yet the strategies for promoting risk score accuracy haven't varied much during that time. Most health plans, physician groups, and vendors promote chart reviews and/or in-home assessments as the primary vehicle for collecting data not perceived to be present in the routine claims submission and adjudication stream. We know that most organizations trying to coalesce encounter data from multiple sources often fail to ensure that all relevant data is ultimately submitted to CMS or a state Medicaid agency. Crucial data, often with significant financial value, frequently gets lost in the data pipeline, somewhere between the provider's billing system and the health plan and/or its vendors. Because 837-formatted data is difficult to read, it complicates payers and vendor’s abilities to track encounter data so that every service delivered to patients is credited to the applicable risk adjustment formula. It is incumbent upon successful risk-adjusted entities to be able to track encounter data, identify processes and/or vendors which may be mangling or losing data, in order to ensure that risk scores are sufficiently accurate to be compliant with plan sponsor requirements and to ensure appropriate revenue to the health plan or provider group.

Description: Employers, health plans, stop-loss insurers and reinsurers are all affected by the high cost of treating cancer. In recent years, cutting-edge pharmaceuticals, bone marrow transplants and CAR-T cell therapies have driven very high cost trends for cancer, with more emerging therapies on the horizon. In this session, we will review these new treatments, showcase models that aid in understanding the range of likely financial effects of the current, expanded, and likely-to-be approved indications for cell therapies that will treat certain patients affected by lymphoma, leukemia, and multiple myeloma. This session will explain important considerations for modeling Medicare, Medicaid versus commercial populations, key risk concerns caused by the size of enrollee pools, and important differences between the various therapies that affect modeling. We will also discuss averted cost, health outcomes, pricing levels, and risks caused by provider billing practices.

Description: 2021 Life Meeting - Session 5E: Importance of Strategic Asset Allocation in a Rapidly Changing Macro Environment 8.31.21 Recording

Description: The topics of ESG (Environmental, Social & Corporate Governance) and sustainability are an increasing area of focus for insurance companies, and thus actuaries. This webcast provides a primer on these topics along with considerations for US valuation actuaries and their evolution in European insurance markets.

Description: Learn how modernization of data, models, and technology are influencing workflows. This webcast will address how workflows are changing in response to new regulatory requirements and the impacts the changes have on modeling and end-to-end future state operating models. Industry leading actuaries will discuss: How team collaboration can increase quality and speed of reporting to internal and external stakeholders How to strengthen controls and compliance frameworks across finance and actuarial departments How to modernize actuarial input/output for strategic analysis and insights How to attract and retain top talent by improving opportunities for actuaries There will also be dedicated time to ask questions of those who have made the transition.

Description: Universal Life with Secondary Guarantees (ULSG) was first introduced in the late 1990's as low-cost, long-term death benefit protection. As this business ages, writers are experiencing pressured earnings from emerging experience, secondary markets for insurance products and low interest rates. In response, writers are sharpening their pencils on experience analysis and risk management with an eye for opportunities to increase the performance of their blocks.

Description: The IFRS 17 implementation deadline is near and companies have decisions to make. While many decisions pertain to specific IFRS 17 requirements, others are more strategic in nature. This session will explore key considerations and decisions faced by stakeholders as they finalize their implementation work and determine ongoing best practices in light of this new standard.